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fail within 10 years.3 Vein graft failure most commonly
occurs secondary to progressive intimal hyperplasia (IH),
a characteristic response of blood vessels to injury that may
lead to luminal narrowing. As part of the adaptive
response to arterial hemodynamic stress, all vein grafts
develop IH to some degree; however, the process by
which this is regulated remains largely unknown. Smooth
muscle cells and extracellular matrix comprise the bulk of
these lesions, and most investigative efforts have focused
on these elements. After implantation, leukocytes are
recruited into the vein graft wall,4 where they may elabo-
rate cytokines capable of broad effects on the growth and
function of resident endothelial and smooth muscle cells.
Variability in the local inflammatory response may be one
of the critical modulating factors determining the final
outcome of graft healing.
Monocytes and their tissue counterparts, macro-
phages, are thought to play a central role in the patho-
genesis of atherosclerosis5,6 as well as in the development
of IH after vascular intervention.7-9 In vein bypass grafts,
monocyte recruitment has been demonstrated in both
Vein bypass grafting is a mainstay of surgical therapy
for patients with occlusive diseases of the coronary and
peripheral arteries. Despite the impressive versatility and
durability of vein grafting, significant morbidity, mortality,
and expenditure incurs from graft failure. In the lower
extremity, typical 5-year patency rates are in the range of
70% to 75%,1,2 and more than 50% of coronary vein grafts
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Objective: Monocyte adhesion to the vessel wall is believed to be an important initiating event in atherosclerosis and
intimal hyperplasia. We hypothesized that occult intraoperative vein injury induces an immediate increase in monocyte
adhesion that may be critical to the development of vein graft disease.
Methods: Vein segments were obtained from patients (n = 23) undergoing lower extremity bypass. The initial segment
(V1, n = 17) was excised immediately at the time of conduit harvest. A second segment (V2, n = 23) was obtained from
the distal conduit just before performing the distal anastomosis. Segments were incubated with radiolabeled THP-1
cells (monocytoid cell line) for 1 hour at 37°C, then rinsed and solubilized for determination of bound radioactivity.
In a subset of grafts (n = 4), THP-1 cells were preincubated with monoclonal antibody (mAB) 7E3 (which binds to
the monocyte integrin Mac-1 at its fibrinogen [Fg]-binding site) or control (mAB 14E11). Fg deposition and endothe-
lial coverage were evaluated by immunohistochemistry (n = 10). Statistical analysis was performed using the paired t
test and analysis of variance. Follow-up graft patency data were obtained and correlated with adhesion values using an
exact test (StatXact, Cytel Software, Cambridge, Mass).
Results: Monocyte adhesion was significantly increased after surgical manipulation (V1, 2400 ± 770 versus V2, 7343 ±
1555 cells/cm2; P < .02). Fg deposition was abundant in V2 sections and not seen in V1. Monocyte adhesion to V2
segments was significantly reduced (58% of control, P < .01) by 7E3 treatment. Graft follow-up was complete with a
mean interval of 11 months. Higher V2 adhesion values were associated with occluded grafts (P = .07). The median
value for the six occluded grafts was 6234 cells/cm2 versus 3892 cells/cm2 for the 17 patent grafts.
Conclusions: Monocyte adhesion to the vein wall is immediately increased after surgical manipulation and is inhibited
by mAB 7E3. Early monocyte adhesion to vein grafts is likely to involve interactions between Mac-1 and Fg.
Heightened levels of monocyte adhesion at implantation may be a marker for subsequent vein graft failure. (J Vasc
Surg 2001;34:923-9.)
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experimental10,11 and clinical12 studies. In one experimen-
tal study, macrophage depletion resulted in suppression of
IH in a rat vein graft model.13 Endothelial cell injury and
activation are postulated as critical early events that lead to
leukocyte recruitment into blood vessels, mediated by
intercellular adhesion molecules (eg, ICAM-1, VCAM-1)
and their leukocyte integrin counter-receptors.14,15
Recent studies have demonstrated that in the setting of
acute, mechanical injury to the vessel wall with extensive
endothelial loss, deposited fibrinogen (Fg) functions as an
important ligand for monocyte adhesion.16 Numerous
studies have documented significant endothelial loss after
standard surgical preparation of veins for bypass graft-
ing.17-19 The kinetics and mechanisms by which leuko-
cytes in general, and monocytes in particular, are recruited
into vein grafts remain largely undefined and may provide
important avenues for targeted intervention.
We hypothesized that occult intraoperative vein graft
injury induces an immediate increase in monocyte adhe-
sion that may play a subsequent role in the development
of IH and graft failure. This study was undertaken to
examine changes in the adhesive properties of vein seg-
ments that occur during the course of lower-extremity
vein graft surgery. Based on our previous work in arterial
injury models,16 we examined the role of Fg and the
monocyte integrin Mac-1 in mediating these early adhe-
sive events. Finally, we sought to correlate these adhesive
properties with subsequent graft function in a pilot clini-
cal study.
METHODS
The Institutional Review Board of the Brigham and
Women’s Hospital approved the use of discarded human
tissue for these studies. During a 10-month period from
1998 to 1999, vein segments were obtained from patients
(n = 23) undergoing lower-extremity bypass operations.
These autogenous vein grafts were employed as in-situ
greater saphenous vein (9), nonreversed greater saphe-
nous vein (7), reversed greater saphenous vein (1), arm
vein (3), or spliced vein (3) conduits. Intraluminal instru-
mentation with a mechanical valvulotome was employed
in the majority (16/23) of grafts. An initial vein segment
(V1, n = 17) was excised immediately at the time of con-
duit harvest and placed in vein storage solution of
Plasmalyte (Baxter Healthcare, Deerfield, Ind) with
heparin (4 µ/mL) and papaverine (12 mg/dL). After
completion of the proximal anastomosis and allowing pul-
satile flow through the graft for several cardiac cycles, a
second vein segment (V2) was obtained from the distal
conduit just before performing the distal anastomosis
(arterialized group, n = 23). The V2 segments were thus
subjected to all of the requisite operative manipulations of
bypass grafting, including gentle but uncontrolled manual
distension with heparinized saline solution, storage at
room temperature for 30 to 60 minutes, and a brief expo-
sure to arterial pressure. As V1 segments were harvested
from the distal end of the exposed vein, and most (16/23)
grafts employed a nonreversed orientation, the V1 and V2
segments were contiguous in the majority of cases. For
reversed, arm, or spliced vein grafts, the geographic rela-
tionship between V1 and V2 segments was inconsistent.
Care was taken to minimize any additional handling of the
vein segments beyond the operative field; they were placed
in containers cooled by ice and transported immediately to
the laboratory for adhesion studies as described below.
Ex vivo monocyte adhesion assay. The human
monocytic cell line THP-1 (American Type Culture
Collection, Manassas, Va) was employed in these stud-
ies.20-22 THP-1 cells were maintained in complete Roswell
Park Memorial Institute medium (Gibco-BRL, Grand
Island, NY), supplemented with 10% (v/v) fetal bovine
serum, 0.2 mM L-glutamine, and antibiotics. Adhesion
assays were performed as previously described.16,23 In
brief, an aliquot of THP-1 cells (1 × 107/mL) was meta-
bolically labeled with 200 µCi of Na251CrO4 (New
England Nuclear Life Science Products, Boston, Mass) for
1 hour at 37°C. The cells were activated with 10 µM N-
formyl-methionyl-leucyl-phenylalanine and 2.5 mM
CaCl2 for 30 minutes at 22°C. Freshly obtained vein seg-
ments were cannulated and gently irrigated with Roswell
Park Memorial Institute medium to rinse away residual
blood. The proximal end of the vein was ligated and the
suspension of labeled THP-1 cells infused to fill and gen-
tly distend the vein. Both V1 and V2 vein segments were
incubated with the same THP-1 preparation for each
experiment. After a 1-hour incubation at 37°C, the veins
were gently flushed with phosphate-buffered saline solu-
tion (1 mL/min) using a programmable infusion pump
(Harvard Apparatus, South Natick, Mass). Rings were
carefully cut from the midportion of both vein segments
(discarding the regions of cannulation and ligature), mea-
sured with calipers to calculate surface area, minced, and
solubilized in 1% Triton X-100 and 10% sodium dodecyl
sulfate (American Bioanalytical, Natick, Mass). After addi-
tion of scintillant, bound radioactivity was measured in a
scintillation counter. An aliquot of 51Cr-labeled THP-1
cells was counted to calculate counts per minute (cpm) per
cell, and adhesion (cells/cm2) was quantitated as (total
specimen cpm)/(cpm/cell)/surface area (cm2).
In a subset of experiments (n = 4), we examined the
role of the monocyte integrin Mac-1 in mediating THP-1
adhesion to arterialized (V2) vein segments. The mono-
clonal antibody (mAB) 7E3, which recognizes an epitope
within the Fg-binding domain of Mac-1,16 was used.
51Cr-labeled THP-1 cells were preincubated with 7E3 or
control mAB 14E11 (25 µg/mL, 30 minutes at 22°C),
then infused into the vessel segments as described above.
Both antibodies were gifts of Dr Dario Altieri of Yale
University.
Immunohistochemistry. Rings were cut from freshly
harvested veins (n = 10 pairs [V1 and V2 segments]),
embedded in optimal cutting temperature compound
(Sakura Finetek, Torrance, Calif) and snap-frozen in liquid
nitrogen. Cryostat sections (6 µm) were adhered to
coated glass slides (VWR Scientific Co, Media, Pa), fixed
in acetone (4°C for 15 minutes), quenched in 30% H2O2,
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and blocked with 10% normal horse serum for 1 hour at
22°C. Primary antibodies to Fg (mouse antihuman Fg,
1:150) and the endothelial cell marker CD31 (JC70/A
mouse antihuman CD31, 1:50), were employed with non-
specific immunoglobulin-G–1 as a negative control. After
incubation with primary antibody at 22°C for 1 to 2
hours, the specimens were washed and vacuum dried, and
a secondary antibody (1:100 biotinylated horse anti-
mouse, Vector Laboratories Inc, Burlingame, Calif) was
applied for 1 hour at 22°C. Visualization of the primary
antibody was performed using an avidin-biotin-peroxidase
complex (ABC Kit, Vector), followed by exposure to 3-
amino-9-ethylcarbazole (AEC Kit, Vector). Counter-
staining was performed using Gill’s hematoxylin.
CD31-positivity was graded as 0, 1, 2, or 3, representing
0%, 1% to 25%, 26% to 75%, and 75% to 100% circumfer-
ential staining, respectively.
Clinical follow-up. Clinical data were retrieved from
a UNIX-based computerized registry in which demo-
graphics, risk factors, procedure variables, and follow-up
information have been prospectively entered for all vascu-
lar surgery patients at our institution since 1975.
Retrospectively, registry data and patient charts were
reviewed to determine graft-related events, and graft
patency was correlated with monocyte adhesion values
(arterialized [V2] segments).
Statistical analysis. Statistical analysis was performed
using the paired t test (7E3 versus 14E11 pretreatment)
and analysis of variance. Follow-up graft patency data was
correlated with adhesion values using an exact test
(StatXact).
RESULTS
THP-1 adhesion to human vein segments was signifi-
cantly increased (>3-fold) after surgical manipulation and
brief arterialization (V2, 7343 ± 1555 cells/cm2 versus
2400 ± 770 cells/cm2; P < .02) (Fig 1). Age, sex, dia-
betes, and conduit type had no discernible influence on
V1 or V2 adhesion values. There was no correlation
between V1 and V2 adhesion values in individual patients.
Pretreatment of THP-1 cells with the mAB 7E3 signifi-
cantly attenuated adhesion to the arterialized V2 segments
(58% of control; P < .01).
In each of the 10 pairs of segments examined, Fg
staining was completely absent in V1 sections and abun-
dant in V2 sections where it was localized to the luminal
surface (Fig 2). CD31 staining demonstrated variable
degrees of endothelial loss in both V1 and V2 segments
(mean score of 2 for both groups; data not shown). The
lack of immediate specimen fixation in this study limits the
interpretation of endothelial integrity.
Graft follow-up was complete in 22 of the 23 patients
with a mean interval of 11 months (range, 15-820 days).
There were six documented graft occlusions; 3 of these
were nonreversed grafts, 2 were in situ grafts, and 1 was in
a composite vein graft. Of these six occlusions, one
occurred in the immediate postoperative period, and was
considered secondary to a marginal caliber vein. There was
one in situ graft failure on day 15, without known cause.
A nonreversed graft failed on postoperative day 33; this
graft had the highest V2 value of the entire series. The
other occlusions occurred at 4 months (in situ), 5 months
(nonreversed), and 7 months (composite vein). The
median value for monocyte adhesion to V2 segments was
6234 cells/cm2 for occluded grafts compared with 3892
cell/cm2 for the patent grafts (Fig 3). This trend linking
V2 adhesion values to graft occlusion did not attain statis-
tical significance (P = .07, exact test).
DISCUSSION
These studies demonstrate that standard surgical
manipulations in lower-extremity vein bypass procedures
induce an immediate increase in the adhesiveness of the
vein for monocytes, establishing the substrate for early
Fig 1. THP-1 adhesion to vein segments from lower-extremity bypass procedures. There is a significant
increase in monocyte adhesion to the V2 segments that were subjected to surgical manipulation and brief
arterialization. SVG, Saphenous vein graft.
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leukocyte recruitment to the graft. Fg, a soluble adhesive
protein with critical functions in both inflammation and
thrombosis, is abundant on the surface of vein grafts at
implantation. Paralleling observations made in other mod-
els of vessel injury,16 THP-1 adhesion to vein grafts was
significantly attenuated by the monoclonal antibody 7E3,
suggesting an important role for Fg/Mac-1 interactions.
Clinical follow-up of our patient group demonstrated a
trend toward an association between THP-1 adhesion val-
ues and graft occlusions, although statistical significance
was not achieved in this small series. Taken together, these
observations led us to hypothesize that occult intraopera-
tive graft injury induces an immediate up-regulation of
luminal interactions with circulating leukocytes, with
potential downstream effects on graft function.
In animal models, placement of a vein segment in the
arterial system leads to variable degrees of endothelial cell
loss followed by a temporal sequence of endothelial repair,
activation and mobilization of smooth muscle cells into a
developing neointima, and gradual thickening of the vein
wall that allows for hemodynamic stabilization of the
graft.24-26 This process of IH within the vein graft is a uni-
versal adaptive response to arterialization; however, an
overexuberant response may lead to progressive luminal
narrowing culminating in graft occlusion. Inflammatory
cells, particularly neutrophils and monocytes, are recruited
into the graft wall and postulated to play a role in the ini-
tiation and propagation of signaling pathways promoting
IH.11,13,27 Monocytes, by virtue of their potent procoag-
ulant and proinflammatory functions, may initiate and
propagate both thrombotic and inflammatory cascades
within the vessel wall. Whereas the role of the mono-
cyte/macrophage in atherogenesis and postangioplasty
restenosis has extensive experimental support, much less is
known about the involvement of these cells in vein graft
stenosis. Recent work by Stark and colleagues10,27 using a
rat vein graft model has demonstrated early infiltration of
monocytes and rapid, sustained elevations of macrophage-
associated cytokines, including monocyte chemotactic
protein-1 (MCP-1). Human endothelial cells as well as
vascular smooth muscle cells and macrophages express
Fig 2. Immunohistochemical staining for Fg on vein segments from lower-extremity grafting procedures. No staining was noted in
unmanipulated V1 segments (right). V2 segments demonstrated diffuse areas of luminal staining (left).
Fig 3. Graft occlusions at 1 year versus monocyte adhesion; the
median value of monocyte adhesion (V2 values) for the grafts that
remained patent at 1 year was 3892 cell/cm2 versus 6234
cell/cm2 for the occluded grafts (P = .07).
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MCP-1,28,29 which may be important in the process of
macrophage accumulation.
Monocyte recruitment to areas of vascular inflamma-
tion and injury is primarily mediated by the β1 and β2-
integrin receptors.14 The presence of intact endothelial
coverage influences the adhesiveness of arteries30 and
veins31 for monocytes. In a rabbit model of acute arterial
injury, we demonstrated that early monocyte adhesion was
markedly inhibited by mAB 7E3.16 This antibody, which
was raised against platelet integrin αIIbβ3 and cross-reacts
with the monocyte integrin αMβ2 (Mac-1), recognizes an
epitope corresponding to the Fg-binding region of Mac-1
and is a potent inhibitor of Fg/Mac-1 interactions. Other
relevant Mac-1 ligands present on the injured vessel wall
include intercellular adhesion molecule-1 (ICAM-1)32 and
platelet glycoprotein Ibα.33 Conflicting reports exist
regarding the effects of 7E3 on Mac-1/ICAM-1 interac-
tions.16,34 Monocytes also express β1-integrins capable of
mediating adhesion to exposed subendothelial matrix com-
ponents such as fibronectin, collagen, and laminin, as well
as vascular cell adhesion molecule-1 expressed by activated
endothelial cells or smooth muscle cells. All of these poten-
tial ligands may be available on the luminal surface within
the first hours of vein graft implantation, and further stud-
ies are needed to determine the relative importance of
these mechanisms. Our studies clearly demonstrate a sig-
nificant role for the 7E3-sensitive pathways.
Plasma Fg levels have been shown to be a potent risk
factor for the development of vein graft failure.35,36 Fg is
required for an organized inflammatory response, as evi-
denced by studies in defibrinogenated animals demonstrat-
ing a marked impairment in monocyte recruitment and the
local response to biomaterials and infectious agents.37 Fg
may mediate monocyte adhesion to the injured vessel by (1)
serving as a direct ligand after its deposition on the exposed
subendothelial matrix16 or (2) serving as a bridging element
between Mac-1 on the monocyte and endothelial cell
ICAM-1.38,39 Fg and its degradation products have potent
downstream effects on vascular cells, including up-regula-
tion of MCP-140 and ICAM-141 expression by endothelial
cells as well as inducing the release of growth factors42,43
capable of driving smooth muscle cell proliferation. Our
observations suggest that an abundance of Fg is immedi-
ately available on the vein graft surface at implantation,
where it may mediate early monocyte adhesion. In this
study we did not measure plasma Fg levels; however, future
investigations will seek to correlate plasma Fg levels with
adhesive properties in human vein grafts.
This article describes our initial investigations of the
acute changes in leukocyte-vessel wall interactions that
occur at the time of surgical bypass grafting in humans. In
addition to small sample size, other important limitations
include the use of a monocyte cell line (versus autogenous
cells), the innate variability in surgical handling and vein
ischemia time, and the use of different types of venous
conduits in this study. In particular, reversed greater
saphenous vein, arm vein, and spliced vein bypass grafts
were under-represented in this study, and further studies
will be needed to determine whether the results may be
generalized. Variability in pre-existing vein pathology and
surgical handling along the course of the vein could influ-
ence cell adhesion as we measured it, and thus the V1 and
V2 segments may not reflect the global state of the pre-
implantation and postimplantation vein. Continued stud-
ies in larger numbers of patients are required to confirm
and extend these observations.
CONCLUSION
Surgical implantation of human veins into the arterial
circulation is associated with an immediate increase in the
adhesiveness of the vein graft for monocytes and a rapid
accumulation of Fg on the luminal surface. Inhibition of
monocyte adhesion by mAB 7E3 suggests that interac-
tions between the leukocyte integrin Mac-1 and Fg are
likely to be involved in these acute responses in vein grafts.
Further studies are required to examine the clinical signif-
icance of these early changes in leukocyte adhesion, their
molecular mechanism, and the influence of other clinical
variables known to be linked to long-term graft function.
We acknowledge the technical assistance of XinXin
Sui, MD, and Kurt K. Rhynhart, MD. Dr Dario Altieri
(Yale University) provided antibodies and scientific advice.
We also gratefully acknowledge the efforts of Julie
Lombarra for maintenance and retrieval of data from the
vascular registry.
REFERENCES
1. Whittemore A. Infrainguinal bypass. In: Rutherford R, editor.
Vascular surgery. Vol I. Philadelphia: WB Saunders; 1995. p. 794-814.
2. Conte MS, Belkin M, Upchurch GR, Mannick JA, Whittemore AD,
Donaldson MC. Impact of increasing comorbidity on infrainguinal
reconstruction: a 20-year perspective. Ann Surg 2001;233:445-52.
3. Campeau L, Enjalbert M, Lesperance J, Vaislic C, Grondin CM,
Bourassa MG. Atherosclerosis and the late closure of aortocoronary
saphenous vein grafts: sequential studies at 2 weeks, 1 year, 5-7 years,
and 10-12 years after surgery. Circulation 1983;68(3 Suppl 2):II1-7.
4. Cox JL, Chaisson DA, Gotleib AI. Stranger in a stranger land: the
pathogenesis of saphenenous vein graft stenosis with emphasis on
structural and functional differences between veins and arteries. Prog
Cardiovasc Dis 1991;34:45-68.
5. Gerrity RG. The role of the monocyte in atherogenesis. 1. Transition
of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol
1981;103:181.
6. Faggiotto A, Ross R. Studies of hypercholesterolemia in the nonhu-
man primate. Arteriosclerosis 1984;4:323.
7. Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruit-
ment and neointimal hyperplasia in rabbits. Coupled inhibitory effects
of heparin. Arterioscler Thromb Vasc Biol 1996;16:1312-8.
8. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte
integrin Mac-1 (CD 11b/CD 18) reduces intimal thickening angio-
plasty or stent implantation in rabbits. Proc Natl Acad Sci USA
1998;95:10134-9.
9. Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M, et al.
Elevated circulating levels of monocyte chemoattractant protein-1 in
patients with restenosis after coronary angioplasty. Arterioscler
Thromb Vasc Biol 2001;21:327-34.
10. Stark VK, Warner TF, Hoch JR. An ultrastructural study of progres-
sive intimal hyperplasia in rat vein grafts. J Vasc Surg 1997;26:94-103.
11. Hoch JR, Stark VK, Hullett DA, Turnipseed WD. Vein graft intimal
hyperplasia: leukocyte and cytokines gene expression. Surgery
1994;116:463-70.
JOURNAL OF VASCULAR SURGERY
928 Eslami et al November 2001
12. Westerband A, Mills JL, Marek JM, Heimark RL, Hunter GC,
Williams SK. Immunocytochemical determination of cell type and
proliferation rate in human vein graft stenosis. J Vasc Surg 1997;25:
64-73.
13. Hoch JR, Stark VK, van Rooijen N, Kim JL, Nutt MP, Warner TF.
Macrophage depletion alters vein graft intimal hyperplasia. Surgery
1999;126:428-37.
14. Hynes RO. Integrins: versatility, modulation and signaling in cell
adhesion. Cell 1992;69:11-25.
15. Altieri DC, Plescia J, Plow EF. The structural motif glycine 190-valine
202 of the fibrinogen gamma chain interacts with CD11b/CD18
(alpha M beta 2, Mac-1) and promotes leukocyte adhesion. J Biol
Chem 1993;268:1847-53.
16. Plescia J, Conte MS, VanMeter G, Ambrosini G, Altieri DC.
Molecular identification of the cross-reacting epitope on alpha M beta
2 integrin I domain recognized by anti-alpha IIb beta 3 monoclonal
antibody 7E3 and its involvement in leukocyte adhesion. J Biol Chem
1998;273:20372-7.
17. Reichel FA, Stewart GJ, Essa N. A transmission and scanning electron
microscopic study of luminal surfaces in Dacron and autogenous vein
bypasses in man and dog. Surgery 1973;74:945-60.
18. Adcock OT Jr, Adcock GLD, Wheeler JR, Gregory RT, Snyder SO Jr,
Gayle RG. Optimal techniques for harvesting and preparation of
reversed autogenous vein grafts for use as arterial substitutes: a review.
Surgery 1984;96:886-94.
19. Ramos JR, Berger K, Mansfield PB, Sauvage LR. Histological fate and
endothelial changes of distended and nondistended vein grafts. Ann
Surg 1976;183:205-28.
20. Tsuuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada
K. Establishment and characterization of a human acute monocytic
leukemia cell line (THP-1). Int J. Cancer 1980;26:171-6.
21. Auwerx J. The human leukemia cell line THP-1: a multifaceted model
for the study of monocyte-macrophage differentiation. Experientia
1991;47:22-31.
22. Krauker T, Oppenheir JJ. Interleukin 1 production by a human
monocytic leukemia cell line. Cell Immunol 1983;80:223-9.
23. Eslami MH, Gangadharan SP, Sui X, Rhynhart KK, Snyder RO, Conte
MS. Gene delivery to in situ veins: differential effects of adenovirus and
adenoassociated viral vectors. J Vasc Surg 2000;31:1149-59.
24. Zwolak RM, Adams MC, Clowes AW. Kinetics of vein graft hyperpla-
sia: association with tangential stress. J Vasc Surg 1987;5:126-36.
25. Schwartz LB, O’Donahue MK, Purut CM, Mikat EM, Hagen PO,
McCann RL. Myointimal thickening in experimental vein grafts is
dependent on wall tension. J Vasc Surg 1992;15:176-86.
26. Davies MG, Hagen PO. Pathophysiology of vein graft failure: a
review. Eur J Vasc Endovasc Surg 1995;9:7-18.
27. Stark VK, Hoch JR, Warner TF, Hullett DA. Monocyte chemotactic
protein -1 expression is associated with the development of vein graft
intimal hyperplasia. Arterioscler Thromb Vasc Biol 1997;17:1614-21.
28. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte
chemoattractant protein-1 in human atheromatous plaques. J Clin
Invest 1991;88:1121-7.
29. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman
HK, et al. Human endothelial cells express CCR2 and respond to
MCP-1: direct role of MCP-1 in angiogeness and tumor progression.
Blood 2000;96:34-40.
30. Gangadharan SP, Eslami MH, Weiss IP, Sui X, Conte MS. Monocyte
adhesion to balloon-injured arteries: the influence of endothelial cell
seeding. J Vasc Surg 2001;33:1247-54.
31. Cooper JP, Newby AC. Monocyte adhesion to human saphenous vein
in vitro. Atherosclerosis 1991;91:85-95.
32. Manka DR, Wiegman P, Din S, Sanders JM, Green SA, Gimple LW,
et al. Arterial injury increases expression of inflammatory adhesion
molecules in the carotid artery of apolipoprotein-E-deficient mice. J
Vasc Res 1999;36:372-8.
33. Simon DI, Chen Z, Xu H, Li CQ, Dong Jf, McIntire LV, et al.
Platelet glycoprotein-Ibalpha is a counter-receptor for leukocyte inte-
grin Mac-1 (CD11b/CD18). J Exp Med 2000;192:193-204.
34. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal anti-
body directed against the platelet glycoprotein IIb/IIIa cross-reacts
with the leukocyte integrin MAC-1 and blocks adhesion to fibrinogen
and ICAM-1. Arterioscler Thromb Vasc Biol 1997;17:528-35.
35. Woodburn KR, Rumley A, Lowe GD, Love JG, Murray GD, Pollock
JG. Clinical, biochemical, and rheologic factors affecting the outcome
of infrainguinal bypass grafting. J Vasc Surg 1996;24:639-46.
36. Woodburn KR, Lowe GD. Fribrinogen, fibrin turnover, endothelial
products and vascular surgery. Br J Surg 1997;84:1059-64.
37. Tang L, Eaton JW. Fibrin(ogen) mediates acute inflammatory
responses to biomaterials. J Exp Med 1993;178:2147-56.
38. Languino LR, Plescia J, Duppernay A, Brian AA, Plow EF, Geltosky JE,
et al. Fibrinogen mediates leukocyte adhesion to vascular endothelium
through an I-CAM-1 dependent pathway. Cell 1993;73:1423-34.
39. Altieri DC, Dupprey A, Plescia J, Thornton GB, Languino LR.
Structural recognition of a novel fibrinogen gamma chain sequence
(117-133) by intercellular adhesion molecule-1 mediates leukocyte-
endothelium interaction. J Biol Chem 1995;270:696-9.
40. Harley SL, Powell JT. Fibrinogen up-regulates the expression of
monocyte chemoattractant protein-1 in human saphenous vein
endothelial cells. Biochem J 1999;341:739-44.
41. Harley SL, Sturge J, Powell JT. Regulation of fibrinogen and its prod-
ucts of intercellular adhesion molecule-1 expression in human saphe-
nous vein endothelial cells. Arterioscler Thromb Vasc Biol 2000;
20:652-8.
42. Pluskota E, D’Souza SE. Fibriongen interactions with ICAM-1
(CD54) regulate endothelial cell survival. Eur J Biochem 2000;267:
4693-704.
43. Lorenzet R, Sobel JH, Bini A, Witte LD. Low molecular weight fi-
brinogen degradation products stimulate the release of growth factors
from endothelial cells. Thromb Haemost 1992;68:357-36.
Dr Michael Golden (Philadelphia, Pa). It was a very nice
paper with a logical extension of the previous work from this
group. The problem of impaired vein graft patency plagues us all,
and unraveling the etiology of the disappointment is extremely
important. Dr Eslami and colleagues have performed a study that
implicates monocyte adhesion and the process and suggests that
increased monocyte adhesion is associated with increased graft
failure. It may incite an inflammatory response or for some other
reason to be associated with later graft events such as graft failure.
Although the authors’ results fail to reach statistical significance,
they are truly thought-provoking, especially when specific agents
to interfere with cell adhesions may be considered.
These are the questions for the authors:
Is there any evidence to support the concept that monocyte
cell lines, THP-1, should bind with the same avidity as the
patient’s own monocytes and therefore allow us to compare bind-
ing quantitatively?
As small segments of the veins were used, was there geo-
graphic variability in the THP-1 binding that might indicate lack
of uniformity and increased sampling error?
The number of grafts were relatively small, and there was a
mixture of graft types and configurations. In addition, some veins
are more difficult than others to use as bypass grafts and require
more handling. Did you notice any relationship between the
amount of handling that any vein segment received and its cell
adhesion characteristics?
And, was there any relationship between the graft configura-
tion and the cell adhesion characteristics? Were there any other
characteristics of the vein grafts or the segments that might have
been expected to be associated with greater problems with graft
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patency or increased graft dysfunction, such as small vein caliber
or vein sclerosis, that may account for the observed differences in
cell adhesions and also patency? Greater dilatation of the smaller
vein will likely result in larger areas of endothelial loss and a
greater opportunity for thrombus formation.
The mean 25-month interval follow-up yielded a 74% pri-
mary patency rate, which seemed to be somewhat low, especially
in view of the excellent historical graft patency results from the
authors. Were there any other characteristics associated with the
failed grafts that might explain the difference in vein graft perfor-
mance compared to the past results? Did the composite arm vein
grafts fare as well as the in situ greater saphenous vein grafts?
And finally, the V2 cell adhesion results suggest a possible
association between increased cell adhesion and graft failure.
There was a large range in the V2 values. Did the V1 values pre-
dict the V2 values, or was there no apparent relationship? What
was the anatomic relationship between V2 and V1 segments?
Were they contiguous?
Thank you.
Dr Mohammad H. Eslami. Thank you for your comments. I
will try to answer all your questions.
The use of THP-1 cell lines was done as these cell lines have
been shown to maintain their integrity in cell cultures. And it
has been shown by many investigators that THP-1 cells closely
approximate monocytes. We agree that use of autogenous
monocytes may be another elegant extension of this study. I
doubt that the results will be any different than what we have
shown. This being human study, and we have small vein seg-
ments to work with, it is hard to directly answer the question of
geographic variability of THP-1 avidity and sampling error.
Perhaps animal studies would be a better avenue to answer this
question.
As far as the choice of conduit and its effects on THP-1 bind-
ing, we evaluated this, and in our patient population the choice of
graft did not appear to have a significant effect on THP-1 bind-
ing. This could be a reflection of small sample size.
As I mentioned in the presentation, there were certain limi-
tations to our study. One was the small sample size, which is
understandably a function of using human vein segments. We did
not study innate pathophysiology of the veins studied in our
experiments. Nonetheless, there are average veins used in the
lower-extremity revascularization procedures. As far as the low 1-
year primary patency, we looked at different comorbidities that
may have caused an increase in THP-1 binding. We could not dis-
cern any factors.
There was no relationship between V1 and V2 values. In
other words, V1 did not predict V2 values.
V1 and V2 segments were not contiguous. V1 segment was
obtained at the time of vein harvest, and this was the distal end of
the vein. V2 segment was obtained at the end of the distal anas-
tomosis from the distal end of the graft.
We cannot say with certainty that the V2 segment is repre-
sentative of the rest of the graft, but we do not think this is much
different in its THP-1 affinity and other characteristics from the
rest of the graft. This being a human study, we may never know
the answer to this with absolute certainty, but perhaps animal
models can be used to shed light on that question.
Dr Gary Nackman (New Brunswick, NJ). I thank the author
for supplying the manuscript. It is a well-written manuscript and
a nicely presented work.
My question for you is, did you analyze whether or not there
was a significant effect of the time factor in terms of the length of
time between V1 was harvested and V2 was harvested and the
binding of THP-1 cells?
In addition, are you measuring bad vein quality or are you
measuring bad handling technique that may occur despite the best
of intentions of treating the vein carefully? Are you finding a pre-
disposition of certain veins to fail, or do you think there is a real
problem with handling because there is a lot of variation in your
numbers. Have you done a positive control? Have you taken a vein
and deliberately beaten it up with a valvulotome or a balloon and
seen what magnitude of increase in binding that you have?
Thank you very much.
Dr Eslami. Thank you for your comments. We did not eval-
uate the time factor per se. Time between V1 and V2 harvest was
dictated by intraoperative factors. We tried very hard to minimize
the time that these vein segments were ischemic by placing them
on ice and expeditiously performing the experiments. We did not
evaluate intraoperative manipulation, but all surgeons involved, as
a rule of their practice, do not overmanipulate vein segments.
We did not perform positive control experiments as you
defined them. However, in parallel experiments in our lab, we
have shown that intraoperative manipulation of rabbit iliac artery
significantly increases THP-1 binding.
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